Abstract:DddA-derived cytosine base editors (DdCBEs) enable the targeted introduction of C·G-to-T·A conversions in mitochondrial DNA (mtDNA). DdCBEs are often deployed as pairs, with each arm comprised of a transcription activator-like effector (TALE), a split double-stranded DNA deaminase half, and a uracil glycosylase inhibitor. This pioneering technology has helped improve our understanding of cellular processes involving mtDNA and has paved the way for the development of models and therapies for genetic disorders caused by pathogenic mtDNA variants. Nonetheless, given the intrinsic properties of TALE proteins, several target sites in human mtDNA remain out of reach to DdCBEs and other TALE-based technologies. Specifically, due to the conventional requirement for a thymine immediately upstream of the TALE target sequences (i.e., the 5′-T constraint), over 150 loci in the human mitochondrial genome are presumed to be inaccessible to DdCBEs. Previous attempts at circumventing this constraint, either by developing monomeric DdCBEs or utilizing DNA-binding domains alternative to TALEs, have resulted in suboptimal specificity profiles with reduced therapeutic potential. Here, aiming to challenge and elucidate the relevance of the 5′-T constraint in the context of DdCBE-mediated mtDNA editing, and to expand the range of motifs that are editable by this technology, we generated αDdCBEs that contain modified TALE proteins engineered to recognize all 5′ bases. Notably, 5′-T-noncompliant, canonical DdCBEs efficiently edited mtDNA at diverse loci. However, DdCBEs were frequently outperformed by αDdCBEs, which consistently displayed significant improvements in activity and specificity, regardless of the 5′-most bases of their TALE binding sites. Furthermore, we showed that αDdCBEs are compatible with DddAtox and its derivatives DddA6, and DddA11, and we validated TALE shifting with αDdCBEs as an effective approach to optimize base editing outcomes at a single target site. Overall, αDdCBEs enable efficient, specific, and unconstrained mitochondrial base editing.

Engineering TALE-linked deaminases to facilitate precision adenine base editing in mitochondrial DNA

Engineered mitochondrial A-to-G editors with enhanced efficiency and targeting scope

Mitochondrial DNA editing in mice with DddA-TALE fusion deaminases

Mitochondrial adenine base editing of mouse somatic tissues via adeno-associated viral delivery

Engineering a Precise Adenine Base Editor with Minimal Bystander Editing.

Precision mitochondrial DNA editing with high-fidelity DddA-derived base editors

Enhanced C‐To‐T and A‐To‐G Base Editing in Mitochondrial DNA with Engineered DdCBE and TALED

Strand-selective base editing of human mitochondrial DNA using mitoBEs

Engineering TadA ortholog-derived cytosine base editor without motif preference and adenosine activity limitation

Engineering precise adenine base editor with infinitesimal rates of bystander mutations and off-target editing

In vivo mitochondrial base editing via adeno-associated viral delivery to mouse post-mitotic tissue

Discovery of Novel Disease-Causing Mutation in SSBP1 and its Correction Using Adenine Base Editor to Improve Mitochondrial Function

Selective Elimination of Mitochondrial Mutations in the Germline by Genome Editing

A Novel Double-Stranded DNA Deaminase-Based and Transcriptional Activator-Assisted Nuclear and Mitochondrial Cytosine Base Editors with Expanded Target Compatibility and Enhanced Activity

More deaminases towards precise editing

Unconstrained Precision Mitochondrial Genome Editing with αDdCBEs

Amelioration of an Inherited Metabolic Liver Disease through Creation of a De Novo Start Codon by Cytidine Base Editing.

Engineering APOBEC3A deaminase for highly accurate and efficient base editing

Directed evolution of adenine base editors with increased activity and therapeutic application

Adenine transversion editors enable precise, efficient A•T-to-C•G base editing in mammalian cells and embryos

Research Progress in Mitochondrial Gene Editing Technology.